Table 1. Multivariate Analysis of Associations Between Individual Comorbidities and Other Covariates With Post–Initial Therapy Mortality (288 Deaths Over 1 Year): Hazard Ratios (HRs) and Corresponding Scores for the AML-CI.
| Comorbidities | HR (95% CI) | Assigned Score for AML-CI | P Value |
|---|---|---|---|
| Cardiac | 1.6 (1.2-2.3) | 1 | .05 |
| Diabetes | 1.1 (0.9-2.8) | 0 | .71 |
| Hepatic | 1.3 (1.0-1.8) | 1 | .04 |
| Infection | 1.3 (0.9-1.8) | 1 | .12 |
| Peptic ulcer | 1.6 (0.9-2.7) | 1 | .11 |
| Renal | |||
| Mild | 1.1 (0.7-1.6) | 0 | .71 |
| Moderate/severe | 1.0 (0.6-1.5) | 0 | .84 |
| Prior malignant neoplasm | 1.2 (0.9-1.6) | 0 | .20 |
| Heart valve disease | 1.5 (0.9-2.8) | 1 | .16 |
| Hyperlipidemia | 0.9 (0.7-1.2) | 0 | .58 |
| Hypertension | 1.1 (0.8-1.4) | 0 | .66 |
| Albumin level, g/dL | |||
| <4.0-3.5 | 1.2 (0.8-1.6) | 0 | .43 |
| <3.5-3.0 | 1.3 (0.9-1.8) | 1 | .20 |
| <3.0 | 1.6 (1.0-2.4) | .04 | |
| Platelet count, ×103 μL | |||
| <100-50 | 1.1 (0.8-1.5) | 0 | .75 |
| <50-20 | 1.0 (0.8-1.5) | 0 | .78 |
| <20 | 1.3 (0.9-2.0) | 1 | .15 |
| LDH level, U/L | |||
| >200-500 | 1.7 (1.2-2.5) | 1 | .004 |
| >500-1000 | 1.8 (1.1-2.7) | 1 | .01 |
| >1000 | 2.2 (1.4-3.5) | 2 | .001 |
| Sex | |||
| Male | 1.1 (0.8-1.4) | 0 | .68 |
| Female | 1 [Reference] | 0 | NA |
| Age, y | |||
| 0-49 | 1 [Reference] | 0 | NA |
| 50-59 | 1.8 (1.2-2.7) | 1 | .007 |
| 60-69 | 2.0 (1.3-3.0) | 2 | .001 |
| ≥70 | 2.5 (1.5-4.0) | <.001 | |
| Cytogenetic/molecular risks | |||
| Favorable | 1 [Reference] | 0 | NA |
| Intermediate | 1.8 (1.2-2.8) | 1 | .009 |
| Adverse | 2.8 (1.9-4.3) | 2 | <.001 |
| Initial regimen intensity | |||
| Low | 1.6 (1.1-2.3) | NA | .008 |
| Intermediate | 1 [Reference] | NA | NA |
| High | 1.2 (0.9-1.8) | NA | .25 |
Abbreviations: AML-CI, acute myeloid leukemia-specific comorbidity index; LDH, lactate dehydrogenase; NA, not applicable.
SI conversion factors: To convert albumin to grams per liter, multiply by 10; to convert LDH to microkatals per liter, multiply by 0.0167.